QYUNS-B2509.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, QYUNS-B (2509.HK) trades at a P/E of 5.89x, P/B of 3.66x, P/S of 3.13x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 2nd percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/B sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 1st percentile over the trailing 10Y window (vs. 1st percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 19th percentile within its industry and the 23rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.92%, ranking at the 96th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 1.7 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. QYUNS-B operates in the Biomedical II sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2509 · SEHK: 2509 · 2509
Want the full picture on whether QYUNS-B (2509.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 5.89 | ||||||
| P/B (MRQ) | 3.66 | ||||||
| P/S (TTM) | 3.13 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 1.92% |